This treatment causes severe bleeding in 4% of patients every year, and up to 1.5% end up dying from bleeding

 

Pulmonary embolism (PE) is the third most common cause of vascular death after myocardial infarction and stroke. In Spain, this pathology is three times less frequent than infarction or stroke, but when it occurs it is associated with a longer hospital stay and greater mortality.

Pulmonary embolism is treated with anticoagulants. However, this treatment causes severe bleeding in 4% of patients every year, and up to 1.5% end up dying from bleeding. Given this situation, it is “important to know which patients may benefit from more aggressive or longer treatment and, on the contrary, which patients need lower doses or a shorter duration of anticoagulant drugs,” says Dr Manuel Monreal, internist and promoter of the RIETE Registry and the websites Trombo.info and Fuente.es.

This was one of the most notable conclusions of the 10th Venous Thromboembolism Multidisciplinary Forum, held in Córdoba on April 3rd and 4th, which was attended by more than 400 physicians from different specialties related to venous thromboembolism (VTE).

International participation

Two of the world’s most renowned experts in thromboembolic disease, Professors Paolo Prandoni, Head of the Department of Cardiology, Thoracic and Vascular Sciences at the University of Padua, and Harry Büller, an internist at the Academic Medical Centre in Amsterdam, attended the Forum and communicated the latest advances in VTE treatment.

The meeting in Córdoba also served to present the latest medical advances with the administration of new anticoagulants. In addition, issues such as the suspension of treatment depending on the patient and new options to prevent and/or to treat the disease better were addressed.

RIETE Registry

In addition to daily experience, much of the current knowledge of VTE is due to the RIETE Registry. It is a database created by Dr Monreal in 2000, in which doctors from all over the world have voluntarily entered the details and course of their patients. This has allowed the RIETE Registry to become a great source of VTE knowledge for experts, today containing information on more than 51,000 patients.

“Little by little the idea took root and grew and the RIETE Registry currently receives contributions from more than 200 hospitals in 20 countries, including Canada and the United States,” says Monreal. Over the years, this registry has become a global reference, thanks to the volume of information that it currently receives. “We know better how to treat the disease in each specific case, which facilitates individualized treatment”, adds the specialist.

“In addition, it allows prognostic scales to be designed, which serve to identify patients at high, medium or low risk of complications and thus expedite the early hospital discharge of low-risk patients or the admission to an intensive care unit of high-risk patients.”

More news